BioAge Stock Dropped Before June Investor Call on Key Drug
BioAge Labs shares fell 0.8% to $16.61 Friday, trailing a stronger Nasdaq. The company set June 4 investor meetings but released no new clinical data. Investors are watching for two mid-2026 proof-of-concept trials of BGE-102, its oral NLRP3 inhibitor for cardiovascular and retinal diseases. April Phase 1 data showed at least 85% median reductions in hsCRP, with no serious adverse events.